Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM15P2G)

Drug Name
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Drug Info
Synonyms
Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol; YC-1
Cross-matching ID
PubChem CID
5712
ChEBI ID
CHEMBL333985
CAS Number
CAS 170632-47-0
TTD Drug ID
D00REK

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Legionellosis 2.10 0.00e+0 51/57 (89.47%) HSPA1A;HSPA8;HSPA6;...
Viral myocarditis 1.95 1.62e-2 53/60 (88.33%) HLA-DQA1;CD40;HLA-DPA1;...
p53 signaling pathway 1.93 1.08e-2 63/73 (86.3%) CDKN1A;SESN1;SERPINB5;...
Herpes simplex virus 1 infection 1.91 8.10e-3 165/498 (33.13%) SRC;CCL5;HLA-DQA1;...
Allograft rejection 1.91 6.48e-3 32/38 (84.21%) HLA-DQA1;CD40;HLA-DPA1;...
Antigen processing and presentation 1.86 9.45e-3 60/78 (76.92%) HSPA1A;HSPA8;HSPA6;...
Type I diabetes mellitus 1.84 1.04e-2 38/43 (88.37%) CPE;HLA-DQA1;HLA-DPA1;...
Measles 1.77 2.23e-2 133/139 (95.68%) HSPA1A;HSPA8;HSPA6;...
Asthma 1.75 2.34e-2 25/31 (80.65%) HLA-DQA1;CD40;CCL11;...
Graft-versus-host disease 1.73 2.43e-2 32/42 (76.19%) HLA-DQA1;HLA-DPA1;FAS;...
Toxoplasmosis 1.68 4.13e-2 103/112 (91.96%) HSPA1A;HSPA8;HSPA6;...
Influenza A 1.68 3.92e-2 156/172 (90.7%) CCL5;HLA-DQA1;IRF7;...
Protein processing in endoplasmic reticulum 1.67 3.93e-2 127/171 (74.27%) HSPA1A;HSPA8;HSPA6;...
Adherens junction -1.90 2.34e-2 63/71 (88.73%) PTPN1;SSX2IP;NLK;...
Mineral absorption -1.95 2.34e-2 48/60 (80%) ATP1B2;HEPH;SLC8A2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 15uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 4uM - 15uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 4uM - 15uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H